We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

PHARMOS, a.s.

Retail & Wholesale > Czech Republic > PHARMOS, a.s.
Change Company
PHARMOS, a.s.
PHARMOS, a.s. is a Czech Republic-based distributor of medications and pharmaceuticals to public and hospital pharmacies in Czech Republic. The company was founded in 1991 and is based in Ostrava, Czech Republic. PHARMOS, a.s. operates as a subsidiary of Ceska Lekarnicka.

Buy all financials of PHARMOS, a.s.

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
          14,215 14,001 10,989 10,702 10,628    
          283 273 209 202 204    
          67.8 10.2 15.3 23.1 31.0    
          16.2 -27.0 6.41 5.89 13.6    
          2.71% -4.58% 1.12% 1.02% 2.33%    
          0.477% 0.073% 0.139% 0.215% 0.291%    
          0.114% -0.193% 0.058% 0.055% 0.128%    
...         617 592 466 438 437    

balance sheet

          4,653 4,324 4,043 3,626 3,459    
          234 225 219 208 218    
          4,378 4,059 3,801 3,413 3,236    
          604 573 576 579 594    
          4,049 3,751 3,467 3,047 2,865    
          11.1 9.42 4.96 1.73 5.98    
          2,158 1,974 1,896 1,579 1,420    
...         19.0 43.5 38.2 30.9 25.7    
...         291% 266% 263% 241% 224%    
... ...       2.67% 1.93% 0.626% 1.04% 0.449%    

cash flow

          -117 136 -147 126 125    
          -4.35 -15.5 -22.7 -10.4 -27.4    
          -3.30 -4.49 -1.91 -110 -36.3    
          -125 116 -172 5.88 61.0    

Download Data
income statement Unit
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
Dividends CZK mil
          14,215 14,001 10,989 10,702 10,628    
          13,933 13,729 10,780 10,500 10,424    
          283 273 209 202 204    
          169 168 132 124 125    
          21.4 69.8 37.8 32.8 26.8    
          92.5 35.1 39.6 45.3 51.8    
          24.8 24.9 24.3 22.2 20.9    
          67.8 10.2 15.3 23.1 31.0    
          47.2 34.2 10.2 15.4 6.37    
          0.000 0.000 0.000 0.000 0.000    
          20.6 -24.0 5.12 7.67 24.6    
          4.37 3.00 -1.29 1.78 10.9    
          0.000 0.000 0.000 0.000 0.000    
          16.2 -27.0 6.41 5.89 13.6    
          4.33 1.80 1.99 31.1 0.000   ...

growth rates

...         0.685% -1.51% -21.5% -2.61% -0.696%    
...         -0.988% 24.8% -28.5% -7.70% -2.91%    
...         -11.3% -62.0% 12.7% 14.4% 14.5%    
...         -15.8% -85.0% 49.9% 50.9% 34.2%    
...         4.00% -216% -121% 49.8% 221%    
...         12.1% -266% -124% -8.23% 132%    

ratios

          2.71% -4.58% 1.12% 1.02% 2.33%    
... ...       0.928% -1.54% 0.396% 0.378% 0.974%    
          1.99% 1.95% 1.90% 1.89% 1.92%    
          0.651% 0.251% 0.360% 0.423% 0.488%    
          0.477% 0.073% 0.139% 0.215% 0.291%    
          0.114% -0.193% 0.058% 0.055% 0.128%    
          26.7% -6.67% 31.0% 528% 0.000%   ...
... ...       2.67% 1.93% 0.626% 1.04% 0.449%    
...         19.0 43.5 38.2 30.9 25.7    

Download Data
balance sheet Unit
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

          234 225 219 208 218    
          228 211 191 174 180    
          3.81 11.1 16.0 22.1 21.1    
          4,378 4,059 3,801 3,413 3,236    
          1,303 1,208 1,288 1,199 1,131    
...         2,461 2,076 1,942 1,561 1,336    
          73.4 189 17.3 23.2 84.2    
          4,653 4,324 4,043 3,626 3,459    
          604 573 576 579 594    
          0.000 0.000 0.000 0.000 0.000    
          4,049 3,751 3,467 3,047 2,865    
          11.1 9.42 4.96 1.73 5.98    
...         0.271 0.113 0.000 0.000 0.000    
...         10.9 9.31 4.96 1.73 5.98    
          2,158 1,974 1,896 1,579 1,420    
...         1,830 1,716 1,530 1,422 1,417    
...         2,080 1,913 1,806 1,497 1,353    
          0.169 0.105 0.000 0.080 2.28    
          4,653 4,324 4,043 3,626 3,459    

growth rates

...         13.9% -7.07% -6.50% -10.3% -4.63%    
...         2.21% -5.18% 0.515% 0.550% 2.57%    
... ...       16.9% -13.1% -0.908% -7.52% -4.73%    
... ...       7.64% -6.26% -10.8% -7.05% -0.364%    

ratios

...         1,830 1,716 1,530 1,422 1,417    
...         1,757 1,526 1,512 1,399 1,333    
...         1,685 1,371 1,424 1,263 1,114    
...         1,919 1,596 1,643 1,471 1,332    
...         291% 266% 263% 241% 224%    
... ...       2.67% 1.93% 0.626% 1.04% 0.449%    

Download Data
cash flow Unit
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

          16.2 -27.0 6.41 5.89 13.6    
          24.8 24.9 24.3 22.2 20.9    
... ...       206 -176 -125 -63.0 -58.6    
... ...       -365 314 -52.8 161 149    
          -117 136 -147 126 125    
          -6.26 -17.6 -23.9 -12.1 -27.5    
          1.91 2.10 1.16 1.75 0.139    
          -4.35 -15.5 -22.7 -10.4 -27.4    
...         -3.15 -4.33 -1.80 -1.99 -31.1    
          0.000 0.000 0.000 0.000 0.000    
... ...       130 -115 -186 -108 -5.18    
          -3.30 -4.49 -1.91 -110 -36.3    
          -125 116 -172 5.88 61.0    

ratios

...         63.2 54.1 64.5 53.2 45.9    
          34.1 32.1 43.6 41.7 39.6    
...         54.5 50.9 61.2 52.0 47.4    
...         42.8 35.4 47.0 42.9 38.1    
          41.0 -2.05 30.7 28.1 34.5    
          -121 120 -170 116 97.2    

Download Data
other data Unit
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

          0.371% -0.601% 0.153% 0.153% 0.385%    
          1.99% 1.95% 1.90% 1.89% 1.92%    
...         617 592 466 438 437    
...         1,290 1,207 1,206 1,103 1,001    
...         22,817 23,611 23,591 23,569 23,899    
          1.19% 1.20% 1.20% 1.16% 1.18%    
          21.2% -12.5% -25.3% 23.2% 44.5%    
... ... ...     14,211 13,955 10,978 10,655 10,612 ... ...
          0.044% 0.126% 0.217% 0.113% 0.259%    
... ... ...     64.5 68.6 44.8 79.3 48.5 ... ...
... ... ...     0.454% 0.490% 0.407% 0.741% 0.457% ... ...

Download Data

PHARMOS, a.s. in Numbers

November 1, 2018
PHARMOS, a.s. in Numbers

This Annual Statistical Dossier offers a summary of PHARMOS, a.s.'s performance between 2006 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested

Read more »

This Annual Statistical Dossier offers a summary of PHARMOS, a.s.'s performance between 2006 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

PHARMOS, a.s. made a net profit of CZK 20.3 mil in 2017, down 54.3% when compared to the last year. Total sales reached CZK 10,899 mil, which is down 3.60% when compared to the previous year.

Historically, the company’s net

Read more »

PHARMOS, a.s. made a net profit of CZK 20.3 mil in 2017, down 54.3% when compared to the last year. Total sales reached CZK 10,899 mil, which is down 3.60% when compared to the previous year.

Historically, the company’s net profit reached an all time high of CZK 44.3 mil in 2016 and an all time low of CZK -27.0 mil in 2012.

In terms of sales, PHARMOS, a.s. reached an all time high of CZK 14,215 mil in 2011 and an all time low of CZK 10,628 mil in 2015.

PHARMOS, a.s.'s net profit has grown nan% a year on average in the last five years while sales have increased by -4.89% a year since 2012.

The firm generated its shareholders an average return on invested capital of 1.10% in the last five years.

As far as PHARMOS, a.s.'s peers are concerned, Geco posted a net profit and sales of CZK 371 mil and CZK 34,305 mil in 2017 and PEAL generated a net profit of CZK 24.0 mil (with sales of CZK 6,370 mil).

You can see all the company’s data at PHARMOS, a.s. Profile, or you can download a report on the company in the report section.

PHARMOS, a.s. made a net profit of CZK CZK 20.3 mil under revenues of CZK 10,899 mil in 2017, down 54.3% and -3.60%, respectively, when compared to the last year.

This translates into a net margin of 0.186%. Historically, the

Read more »

PHARMOS, a.s. made a net profit of CZK CZK 20.3 mil under revenues of CZK 10,899 mil in 2017, down 54.3% and -3.60%, respectively, when compared to the last year.

This translates into a net margin of 0.186%. Historically, the firm’s net margin reached an all time high of 0.392% in 2016 and an all time low of -0.193% in 2012. The average net margin in the last five years amounted to 0.164%.

On the operating level, EBITDA margin reached 0.323% and EBIT amounted to 0.494% of sales in 2017.

As far as PHARMOS, a.s.'s peers are concerned, Geco posted net and EBITDA margin of 1.08% and 1.48%, respectively in 2017 and PEAL generated margins of 0.377% and 0.721%.

You can see all the company’s data at PHARMOS, a.s. Profile, or you can download a report on the company in the report section.

PHARMOS, a.s.'s net debt reached CZK 1,352 mil and accounted for 211% of equity at the end of 2017. The ratio is down 1.28% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time

Read more »

PHARMOS, a.s.'s net debt reached CZK 1,352 mil and accounted for 211% of equity at the end of 2017. The ratio is down 1.28% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 334% in 2007 and an all time low of 211% in 2017.

When compared to EBITDA, net debt amounted to 25.1x at the end of the year. The ratio reached an all time high of 43.5 in 2012 and an all time low of 9.83 in 2008.

As far as PHARMOS, a.s.'s peers are concerned, Geco posted net debt to equity of 47.3%x and 0.592x when compared to EBITDA at the end of 2017. PEAL ended the year 2017 with a net debt at 125%x of equity and 3.56x when compared to its EBITDA while PEAL had net debt at 125%x of equity and 3.56x to EBITDA at the end of the year.

You can see all the company’s data at PHARMOS, a.s. Profile, or you can download a report on the company in the report section.

PHARMOS, a.s. employed 456 persons in 2017, up 0.441% when compared to the previous year. Historically, the firm's workforce hit an all time high of 672 in 2007 and an all time low of 437 in 2015.

Average cost reached USD 1,260

Read more »

PHARMOS, a.s. employed 456 persons in 2017, up 0.441% when compared to the previous year. Historically, the firm's workforce hit an all time high of 672 in 2007 and an all time low of 437 in 2015.

Average cost reached USD 1,260 per month per employee per month, 21.1% more than a year ago. This figure was USD 1,006 per month per month some 10 years ago.

As far as PHARMOS, a.s.'s peers are concerned, Geco employed some 1,708 people in 2017 while PEAL was operating with 523 staff.

You can see all the company’s data at PHARMOS, a.s. Profile, or you can download a report on the company in the report section.

See all charts of the company »
PHARMOS's employees rose 0.441% to 456 in 2017
PHARMOS's net profit fell 54.3% to CZK 20.3 mil in 2017
PHARMOS's net profit fell 54.3% to CZK 20.3 mil in 2017
PHARMOS's Capital Expenditures rose 249% to CZK 33.3 mil in 2017
PHARMOS's Cash & Cash Equivalents fell 58.0% to CZK 32.9 mil in 2017
PHARMOS's Total Cash From Operations rose 367% to CZK 68.2 mil in 2017
PHARMOS's Net Debt/EBITDA rose 74.3% to 25.1 in 2017
PHARMOS's ROCE fell 61.3% to 1.05% in 2017
PHARMOS's Net Margin fell 52.6% to 0.186% in 2017